The Society of Practising Veterinary Surgeons (SPVS) has published its 2014 Salaries Survey which showed that the gender pay gap has closed from 15% last year to 10.8% this.
However, the association notes that this is still slightly higher than the gap reported for all professions in the UK, so there remains work to be done.
The survey, which is the largest of its kind and drew responses from 1,878 vets, nurses, practice managers and receptionists also found that:
Peter Brown, SPVS Treasurer and author of the report comments: "The SPVS Salaries Survey is intended as a benchmark to give some indication of what is being paid as the 'going rate' rather than to advise on what employees should be paid. Having said that, we would urge all veterinary practices to continue working to ensure that equal rates of pay are given for positions of equal status. Although the gender gap has closed up, it is still too big."
The annual SPVS Salaries Survey is free of charge to SPVS members and costs £150 for non-members. For more information, call 01926 410454 or visit www.spvs.org.uk.
The company says that the effervescent tablet presentation was designed to significantly improve vaccination practices for poultry producers while maintaining reliable virus protection.
Boehringer says this dispensing form reduces the risk of stock solution contamination and, when compared to glass vials, the small blister packs make vaccine management safer for operators, take up less room in the fridge and reduce packaging waste by 90%.
HatchPak IB H120 NeO will be available shortly in packs of 10 tablets of 1000 doses or 10 tablets of 2000 doses.
Callum Blair, Boehringer Ingelheim Avian and Swine Brand Manager, said: "The addition of HatchPak IB H120 NeO to our NeO product portfolio is evidence of our continued investment in the poultry sector."
EthyCalm is sprayed directly on the skin, or, for more fractious patients, can be applied with a swab.
Invicta says that unlike other products the effect is instant and EthyCalm leaves no residue on the skin surface.
The improved product, EthyCalm Plus, contains 50% more product (good for over 100 applications) and incorporates a new 'on-off' switch for easier application. It is also now packed in a 'no-roll' case to protect from damage.
Rob Watkins, Managing Director of Invicta, said: "EthyCalm has been an incredibly popular product with nurses and vets. As a small company we always listen to our customers and have taken the opportunity to incorporate suggestions for improvement. The result is EthyCalm Plus which offers significant enhancement over the original product".
EthyCalm Plus is available from veterinary wholesalers and for a limited time the price has been held at £25 each.
Animals Count, which describes itself as a political party for people and animals, will launch its EU election manifesto on 24th May from 12 noon at the Kings Oak, Loughton, where it will be putting into practice one of its proposed policies: subsidised basic and emergency animal health care for animals. Animals Count President and veterinarian, Andrew Knight, will provide free dog consultations and animal health care advice for all companion animals.
Animals Count will contest the European Parliament elections, taking place on the 4th of June. It hopes to end farming with poor welfare consequences for animals, long distance live animal transport, all hunting for sport, and introduce an EU-wide subsidised basic animal health care system.
Animals Count Leader, Jasmijn de Boo MSc., said: "Concern for animals has long been a mainstream priority, yet remains poorly represented by most political parties. In several countries political parties for animals have formed to meet this need. The Dutch Party for the Animals from which we grew now has 20 elected representatives, including 2 MPs and one senator."
"The EU elections are particularly important for people and animals. Around half the EC budget is spent on agriculture. Given today's economic climate there's never been a better time to re-examine the massive expenditure of tax-payer money on farming methods known to be strongly associated with poor animal welfare and serious environmental damage."
Miss de Boo, 33, Alex Bourke, 47, Vice-chair of Animals Count and best-selling author of the 'Vegetarian Guides' book series, and Richard Deboo, 41, City professional and public speaker on animal issues, will contest the June EU elections in the Eastern region of the UK. Animals Count's ultimate goal is a world in which animals are not exploited, and are treated as sentient beings.
According to the company, the new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM). Twelve hours after the injection is administered, treatment can be continued by the dog's owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
Ruth Willis BVM&S DVC MRCVS, RCVS Recognised Specialist in Cardiology said: "Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM."
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25 kg.
In association with the Vets Now emergency treatment service, Boehringer has produced an algorithm which features step-by-step guidance on the recommended treatment protocol for dogs with acute congestive heart failure due to MVD or DCM, together with point of sale material including shelf wobblers for use in practice to raise awareness of the product.
The company is also hosting a free cardiology webinar presented by Ruth Willis entitled 'Acute CHF - a stress free approach'. The online seminar takes place at 8.00pm on Tuesday 19 February and counts for one hour's CPD. The webinar will be available to view after the live event on demand. To register, visit http://www.bi-academy.co.uk/.
For further information, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
The new product, which is for the management of any condition where eye health is supported by providing additional moisture or lubrication, is suitable for dogs, cats, horses, rabbits and other animals.
Oculeze contains glycerine (0.8%), Aloe vera, chamomile and propolis extract, the latter of which contains polyphenols which Millpledge says have been shown to support corneal health by multiple mechanisms of action including modulation of the tear film and a reduction in inflammation, apoptosis and oxidative stress1.
Millpledge says Oculeze lasts longer on the ocular surface than non-lipid lubricants2 because it evaporates more slowly3.
This prolonged action means fewer administrations, which should help client compliance.
Oculeze comes in two sizes - a 10 millilitre bottle and a pack of ten resealable 0.6 millilitre vials, suitable for short term use and travel.
The 10ml bottle includes a filter, preserving sterility for up to three months after opening.
Oculeze is available direct from Millpledge or from your usual wholesaler.
https://millpledge.com/shop/oculeze
sales@millpledge.com
References
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
Boehringer Ingelheim has announced that Vetmedin Chewable Tablets have been licensed for treating pre-clinical dilated cardiomyopathy (DCM) in Doberman Pinschers1.
Boehringer says DCM is the most common form of cardiomyopathy in dogs and the second most common form of acquired heart disease in dogs. Typically, up to half (25 - 50%) of Doberman Pinschers develop DCM in their lifetime and before congestive heart failure (CHF) develops, over a quarter (25 - 30%) of these dogs will suffer sudden death. Despite optimal treatment, survival time once in CHF is short at just 2 - 4 months, with a fatality rate of at least 90% after a year.
The new indication was granted following a study which showed that early intervention with Vetmedin at pre-clinical stages in Dobermans can significantly delay the onset of CHF, increasing life expectancy and quality of life for patients2.
Robert Lucy, Vetmedin brand manager, Boehringer Ingelheim UK, said: "The PROTECT study, and the resulting new indication for Vetmedin is groundbreaking. For the first time ever, we are now not only able to manage congestive heart failure, but to significantly delay it. By acting sooner, we'll be able to alter the course of disease progression, ultimately increasing survival and allowing more pet owners to spend more time with their beloved dogs. Key to this will be giving vets the support and confidence in recognising the subtle signs of pre-clinical DCM. We plan to support veterinary professionals with new educational materials, including a screening algorithm, to help the diagnostic process."
Traditionally, there have been no licensed therapies available to vets to slow the progression of heart disease during the pre-clinical stage. However, peer-reviewed independent data from PROTECT, the first study in veterinary cardiology of its kind, proves that early intervention with Vetmedin at pre-clinical stages in Dobermans Pinschers can significantly delay the onset of CHF, increasing life expectancy and quality of life for patients.
Furthermore, the research found that among female dogs that had problems giving birth, French bulldog bitches are then 2.4 times more likely to undergo invasive caesarean sections than crossbred dogs.
This compared to brachycephalic bitches in general, which the RVC researchers found are 1.54 times more likely to need a caesarean compared with their longer-nosed pure breed or crossbred counterparts.
As part of the research, academics studied 20,000 bitches that required emergency treatment at 50 Vets Now veterinary clinics between 2012 and 2014.
Their findings, published in two papers in The Veterinary Record, highlight the substantial risks that bitches and their puppies face during the birthing process.
According to the first paper1, 3.7% of female dogs suffer from dystocia. Alongside French bulldogs, other pure breeds such as Boston terriers, chihuahuas and pugs, are also particularly at risk of birthing problems. Compared to crossbred bitches, Boston terriers are 12.9 times more likely to face birthing issues, pugs 11.3 times more likely and chihuahuas 10.4 times more likely.
The second paper2, which is available open access, examines the effects of difficult births more closely. It found that on average, 25% of puppies and 1.7% of the bitches do not survive problem births. Apart from the risk of death, problem births also mean that many bitches have to undergo painful and invasive surgery, with 48.6% of problem births needing caesarean surgery.
Bulldogs (also known as British Bulldogs), border terriers and golden retrievers were the top three breeds at risk of caesarean section once they have difficulty giving birth. Bulldogs are 7.6 times more likely, border terriers are 4.9 times more likely and golden retrievers are 4.1 times more likely to need the procedure compared with crossbreeds.
RVC veterinary epidemiologist and VetCompass researcher Dr Dan O’Neill said: "This new research is another piece of evidence suggesting that mankind may have gone too far in modifying dog breed shapes towards extreme conformation that can interfere with basic biological functions. We all need to fall back in love with dog-shaped dogs and move away from the current fascination with extreme-shaped dogs."
O’Neill, DG., O’Sullivan, AM., Manson, EA., Church, DB., McGreevy, PD., Boag, AK., Brodbelt, DC.(2019) Canine dystocia in 50 UK first-opinion emergency care veterinary practices: clinical management and outcomes Veterinary Record Published Online First:04 February 2019. doi: 10.1136/vr.104944.
Dechra says Finilac inhibits prolactin secretion by the pituitary gland and therefore inhibits all prolactin-dependent processes, meaning it can also suppress lactation in bitches and queens.
Finilac, which contains cabergoline (50 microgram/ml), is presented as a liquid which can be given orally or in food. It is available in 3 ml, 10 ml, 15 ml and 25 ml bottles with 1 ml and 2.5 ml syringes included in every pack to ensure accurate dosing.
The dosage is 0.1 ml/kg bodyweight once daily for four to six consecutive days, depending on the severity of the clinical condition. Maximum inhibition of prolactin secretion is achieved after four to eight hours.
Dechra Brand Manager Carol Morgan said: "A false pregnancy can be a distressing condition for an animal and its owner so Finilac offers a fresh approach for cases with more severe symptoms that require veterinary intervention.
"It is easy to administer either directly into the mouth or by mixing with food and it doesn’t need to be transported or stored in the refrigerator, making it ideal as an ‘at home’ treatment that can be administered by owners."
Cancer Care for Pets offers both clinical and palliative care for pets with cancer, supporting the work of the first opinion team at Donaldson's and taking referral cases from far and wide.
Neil and Kirsty have worked in practice together in the Yorkshire area for seven years, working with owners and families to create treatment plans involving diagnostic investigations, specialised imaging, surgery, chemotherapy and palliative care.
Neil said: "As far as we know, we are one of very few services to offer this combination of veterinary and nurse-led consultations, where comprehensive cancer treatment and care plans are developed together with owners. We have worked hard to instil our team approach where, following surgery and treatment, the Cancer Care team, the owner and the referring practice are all involved in the pet’s ongoing care and wellbeing."
Kirsty said: “Neil and I do many of our consults together. Neil will give his clinical overview and I will help owners to process and understand the treatment and the next steps for their pet.
“It was incredibly important to us to create a friendly, welcoming environment in our new dedicated consultation area at the hospital. We need people to trust us and be honest about how fit and well their pet really is, in the knowledge we are not automatically going to tell them there is nothing we can offer them. Treating cancer is about life, not managing a death, and making sure that the pet’s life – even if it is limited – is as good as it can be.”
Neil said: "The Cancer Care for Pets team will be working alongside the wider Donaldson’s veterinary and nursing teams and we are keen to learn from each other. The facilities at the hospital are second to none, particularly our new purpose-built consultation area, the practice’s new CT scanner and the high spec operating facilities. Donaldson’s also has a well-respected rehabilitation and pain clinician with whom we can work closely to help our older patients to keep mobile, flexible and maintain activity levels.”
Neil and Kirsty are supported by a third member of the Cancer Care for Pets team, oncology nurse Jenna Carrick RVN.
Cancer Care for Pets is now accepting referrals. Contact: info@cancercareforpets.co.uk or 01484 242911.
Merial has launched Merilym 3, the first Lyme disease vaccine available in the UK.
Lyme disease is the most common vector-borne disease in Europe and there has been an increase of over 300% in the number of reported human cases in the UK since 20011. Caused by infection with bacteria from the Borrelia burgdorferi group, the disease is transmitted by Ixodes spp. ticks.
Merial says the vaccine contains inactivated antigens from Borrelia burgdorferi sensu stricto, Borrelia afzelli and Borrelia garinii, so provides broad spectrum immunity against infection. Vaccination with Merilym 3 induces high levels of antibodies against a key bacterial antigen, which are ingested by the tick during blood feeding and subsequently bind to the bacteria in the tick gut, reducing the risk of transmission from the tick to the host.
For use in dogs, the vaccine can be administered to puppies from 12 weeks old, with a primary vaccination course of two injections, three weeks apart, followed by annual boosters. It is available in packs of 10 doses.
For more information, speak to your local Merial Territory Manager.
Reference
Corona Detect is a first-line screening tool for detecting exposure to feline coronavirus (FCoV). It can be coupled with the Idexx FIP Virus RealPCR to follow up coronavirus-positive cats exhibiting clinical signs suspected to be FIP. The Idexx FIP Virus RealPCR evaluates for mutations of feline coronavirus to the pathogenic FIPV biotype.
Idexx says that this new two-tier diagnostic approach will help veterinary surgeons rule out or positively diagnose FIP, a condition which has hitherto been extremely difficult and frustrating to diagnose.
Simon Wootton, Idexx’s Companion Animal Group’s Northern European Marketing Manager said: "FIP is a terrible disease, so being able to screen and either confirm or rule out exposure to FCoV is an important additional step in the diagnosis options available to vets. With the ability to screen in minutes, practitioners will be able to decide whether to perform confirmatory and potentially invasive tests for the specific FIPV mutations. This obviously brings benefits to aid pet owners."
Further information is available on the company’s website – www.idexx.eu
Fitzpatrick Referrals has carried out a world-first procedure in which an American Bulldog was fitted with a prosthetic hip and femur with a special in-growth attachment which effectively re-attaches the tendons and muscles to the artificial limb.
The procedure took place after 8 year old Roly was diagnosed with cancer in his rear hind leg earlier this year. It involved a highly complex two-hour operation, during which Dr Noel Fitzpatrick, a neuro-orthopaedic veterinary surgeon, replaced the cancerous femur bone and hip joint with a specially constructed artificial prosthesis, while re-attaching the musculature and realigning the relative position of the joint to restore perfect movement to the dog.
The prosthesis was designed through a collaboration between Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science; veterinary surgeon Noel Fitzpatrick and Jay Meswania from specialist implant manufacturer OrthoFitz.
Professor Blunn said: "What is significant about the design is the way in which it sandwiches tissue and metal together overlaying the gluteal muscles onto the top of the endoprosthetic femur - alternating tendon, synthetic Dacron mesh, tendon, synthetic Dacron mesh, tendon and finally trabecular metal - which has a honeycomb surface resembling a series of small chambers. In this way, the hope is that the Sharpeys fibres which attach tendons of muscles to the bone will grow into the trabecular metal surface and permanently adhere to it."
"This truly remarkable achievement was made possible through the convergence of biomechanics, biology and surgical innovation," said Noel Fitzpatrick. "We tapped into the evidence provided by the CT and MRI scanners we have in place at the practice, so that the data collected about Roly during clinical diagnosis was used to design and construct an artificial femur which exactly mirrored his original limb. It has been constructed rather like a telescope - one section fitting inside the adjoining section, so that we get maximum flexibility and traction during motion."
Noel added: "Hip replacement is common here. We do more than 50 a year, on animals as small as a cat or a Chihuahua. But this hip replacement was special, and to my knowledge, the first of its kind in the world. It's important though to emphasise that this technology must only be employed when it is in the best interests of the individual patient. It's not enough to be able to do something; it must be done for the right reason in every case without exception. It must be ethically right. It's also important to emphasise that Roly will probably not live for a normal lifetime because bone cancer generally spreads to the lungs over time in spite of chemotherapy. However, this technology is equally applicable for dogs and cats affected by trauma who will likely live longer. My job is to look after my patients as best I can and to be honest with their guardians and give them options. What I do is provide pain free functional quality of life for as long as my patient is alive. That's important and that's special, but the decision must remain with each and every individual animal owner".
According to the team, this development also has potentialy life-changing implications for human patients such as motorcycle accident victims, where a key challenge to recovery may be successfully re-attaching the kneecap tendon onto the top of the tibia in the lower leg, and injured sports players with ruptured repairing ruptured tendons.
Click here to view the x-rays of this case in the VetSurgeon Gallery.
The raw pet food poster gives owners guidance on how to handle and prepare their pet’s meal when feeding a commercial raw pet food. The guinea pig one gives guidance on what owners need to feed their guinea pig to ensure good health and well-being. It is also available to download from: www.pfma.org.uk/the-importance-of-hay-poster-guinea-pigs.
The PFMA will be giving away free copies of both the posters, alongside a range of other fact sheets and posters, at the London Vet Show.
The Association is also offering veterinary surgeons the chance to win a £100 high street shopping voucher by taking part in its annual survey focusing on health and feeding trends, which can be done here: www.surveymonkey.com/r/PFMALVS19
The survey closes on Sunday 17th November.
Ms Evans was charged with causing or allowing a veterinary nurse colleague to order a prescription-only medicine from a practice supplier knowing that it was intended for human use, and made a false entry prescribing the medication on the clinical records of a cat belonging to her nurse colleague.
She was also charged with falsely recording details purporting to be the results of the blood tests on cat and then entering notes on the animal's clinical history which falsely indicated that there had been a meaningful result, and then indicating to the animal's owner that there had been a meaningful result, when in fact the tests had failed to produce any meaningful results.
The final charge was that her conduct in making the false entry for the prescription-only medication, and all elements of the second charge was dishonest and misleading.
Ms Evans admitted the first charge on the basis that she had allowed rather than caused the order to be made, all the other facts of this charge were admitted.
She admitted the second charge on the basis that she had failed to inform the cat’s owner of the test results, all the other facts of this charge were admitted.
She also admitted that elements of her conduct had been dishonest and misleading.
Having found the charges proven by Ms Evans’ admissions, the Committee considered whether her admitted actions and conduct amounted to serious professional misconduct.
Ms Evans, through her legal counsel, accepted that the admitted charges passed the threshold for serious professional misconduct, though that question still needed to be determined independently by the Committee.
The Committee found that Dr Evans’ conduct had breached several key parts of the Code of Professional Conduct and its supporting guidance, particularly around honesty and integrity.
It also found aggravating factors in this case, including the risk to human health by allowing the prescription-only medication to be ordered knowing it was for human use, the abuse of her professional position, the breach of client trust, the potential adverse impact on the welfare of the cat for whom she falsified the blood test records, and the potential adverse impact on the welfare of the cat for whom she had falsely recorded the prescription-only medicine.
The Committee found no mitigating factors relating to the facts.
Paul Morris, chairing the Committee and speaking on its behalf, said in relation to the first charge: “In the Committee’s view, this irresponsible approach to a prescription-only medicine risked human health, potentially compromised an animal’s welfare, since the clinical record suggested the cat had been given Fluconazole when it had not, constituted an abuse of the trust placed in her as a registered veterinary surgeon and was in breach of legal provisions designed to safeguard human health.
“Such behaviour falls far below the standard expected of a registered veterinary surgeon, undermines public confidence in the profession and would be considered deplorable by colleagues and the public alike.
"The Committee was thus satisfied that charge 1 on its own amounts to disgraceful conduct in a professional respect.”
He added: “Acting dishonestly runs contrary to one of the most fundamental principles of the profession.
"The public need to know that they can rely on the honesty and integrity of the people to whom they entrust the care and welfare of their animals.
“Further, Dr Evans’ conduct in both incidents had the potential to undermine public confidence in the profession of veterinary surgery and bring the profession into disrepute.
"In all the circumstances, the Committee was satisfied that Dr Evans’ behaviour as reflected in charge 2 fell far short of the standard expected of a veterinary surgeon and amounted to disgraceful conduct.
“Accordingly, the Committee found proved the allegation that Dr Evans was guilty of disgraceful conduct in a professional respect.”
Having found serious professional misconduct in relation to all charges, the Committee considered what the most appropriate and proportionate sanction would be for Ms Evans’ actions and conduct.
In doing so, it considered 137 positive references and testimonials from Dr Evans’ professional colleagues and clients, poor staff morale at the practice at the time as well as compelling, exceptional evidence relating to Dr Evans’s health at the time of the two incidents.
In mitigation, the Committee considered the fact that Dr Evans had no previous disciplinary history and had a hitherto unblemished career as a veterinary surgeon; her open and frank admissions; the circumstances of pressures at work exacerbated by Dr Evans’ desire to please everyone and not let anyone down; the fact that Dr Evans was feeling very isolated; the significant insight into her conduct and its impact; effective and targeted remediation to ensure there would be no likelihood of the conduct being repeated; genuine expressions or remorse and apology; support from her employers; and the very significant number of positive testimonials.
Summing up the Committee’s decision on sanction, Mr Morris said “In all the, somewhat exceptional, circumstances of this case, the Committee was satisfied that a reprimand and a warning not to behave in this way again, would provide adequate protection to animals, as it was satisfied Dr Evans was most unlikely to ever make such a flawed set of decisions again.
“The Committee was satisfied that Dr Evans does not represent a risk to animals going forward, indeed from the character evidence it is clear that she always puts the welfare of animals first.
"She has also shown, since this episode, that she can work under pressure and not resort to making bad decisions and thus the Committee considered the wider public interest would best be served in this case by a reprimand and a warning.
“Notwithstanding the serious nature of Dr Evans' conduct, the Committee was satisfied that a fully informed member of the public would not be shocked if Dr Evans were allowed to continue to practise.
“The decision of this Committee is, therefore, that Dr Evans be reprimanded and warned about her behaviour.
"Dr Evans should, however, be under no illusion of how serious it is to have a finding of disgraceful conduct in a professional respect made against her and she should not take lightly the decision of this Committee to reprimand and warn her.”
www.rcvs.org.uk/disciplinary
Ms Mulvey faced a total of nine charges against her:
Ms Mulvey did not respond to the charges, was not present at the hearing and was not represented.
She told the College that she couldn't attend for health reasons, but did not then provide any medical evidence and did not apply for a remote hearing, which was offered.
She had appeared before the Disciplinary Committee twice previously, facing a number of similar charges.
In 2016/2017, Ms Mulvey admitted all charges she was faced with and was found guilty of disgraceful conduct in a professional respect.
The Committee then decided to postpone the sanction for a period of one year.
In 2019, Ms Mulvey appeared before the Committee for the resumed sanction hearing and faced further new charges relating to failures to provide clinical history, failing to communicate with clients, failing to respond to requests for information from the College concerning complaints made against her, continuing professional development and indemnity insurance.
Ms Mulvey admitted the new charges and that she was guilty of disgraceful conduct in a professional respect, for which she was struck off for six months.
Taking into account the fact that this was not Ms Mulvey’s first time before the Committee, as well as new accompanying evidence, the Committee considered the facts of each subsection of each charge individually.
The Committee found all charges proved, apart from one subsection of charge 1.
The Committee then went on to decide if Ms Mulvey was guilty of disgraceful conduct in a professional respect, noting that it was entitled to consider the facts on a cumulative basis.
In other words, whilst any one charge may not fall far below the relevant standard expected of a veterinary surgeon on a standalone basis, it may when considered in conjunction with other failings that have been found proved.
The Committee found a number of aggravating factors in the case, including actual injury to animals (including death and amputation), dishonesty, breach of trust, sustained behaviour, disregard of the role of the RCVS, lack of insight by the defendant and previous adverse findings.
There were no mitigating factors.
The Committee then went on to decide upon a sanction.
Paul Morris, chairing the Committee and speaking on its behalf, said: “The Committee found that Dr Mulvey has demonstrated a wilful disregard for the role of her regulator and the systems that regulate the profession which are designed to ensure animal welfare.
"She has failed to learn from, or respond to in any meaningful way, her previous appearances before her regulator and advice given.
"The instant charges found proved dated back to shortly after the earlier suspension had elapsed.
"The Committee further noted that, if a period of suspension were to be imposed, at the end of the suspension Dr Mulvey would be entitled to resume practice without any preconditions.
“This is a case involving serious malpractice.
"It was sustained over a period of time.
"It followed previous adverse findings for almost identical failures.
"From as long ago as 2013, Dr Mulvey was given ample opportunity and support to remedy the deficiencies in her practice, which she squandered.
"Dr Mulvey’s conduct had very serious consequences for animal welfare.
"She continued, and continues, to display a wilful disregard for her responsibilities as a veterinary surgeon under the Code of Professional Conduct.
"Dr Mulvey’s conduct was a gross departure from the conduct expected of a veterinary surgeon.
“Dr Mulvey’s disgraceful conduct is so serious that removal from the Register is the only means of protecting animals and the wider public interest which includes protection of the public, the maintenance of public confidence in the profession, and the upholding of standards.”
Dr Mulvey has 28 days from being notified of her removal from the Register to lodge an appeal with the Privy Council.
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Poulvac CVI + HVT Marek’s vaccine provides the combination of the Rispens CVI strain and the HVT strain.
Zoetis says this combination of serotypes has long been recognised for providing strong, reliable protection against the disease, effective even against the very virulent pathotype of the virus.
John Kenyon, Zoetis National Veterinary Manager for Poultry said: "Marek’s disease remains a major problem for the poultry industry.
"To increase protection, it is a good idea to combine the CVI and HVT vaccine strains, and the new supplies of our vaccine help to make this more feasible.
“Currently in some longer-lived broilers and backyard laying hens a vaccine composed of just a single serotype is used, but it is advantageous to use a combination of serotypes to boost immunity further.”
Marek’s vaccination with Poulvac CVI + HVT can be performed in the hatchery at day of age via subcutaneous or intramuscular injection.
The Zoetis vaccine is supported with a range of services, including hatchery and vaccine audits, vaccine training and technical assistance.
The Group has trained almost 100 of its staff as 'mental health first aiders'.
Michelle O’Connor, the Linnaeus Group’s people and culture director (pictured right), said: "Veterinarians are three to four times more likely to die by suicide than workers from any other industry.
"Because of this alarming statistic, we have put wellbeing at the very forefront of our strategy and have so far trained nearly 100 mental health first aiders within the group.
The Linnaeus volunteers, who are taken from both office and clinical roles, have all attended a training course run by Mental Health First Aid England (MHFA) to acquire the skills to support their own and others’ wellbeing.
The MHFA course trains people to identify the signs of mental ill health, to break down the stigma and barriers surrounding mental health and listen to colleagues in a non-judgemental way, and to help direct those suffering from issues to the support and guidance that’s available.
Michelle added: "We realise training on how to spot signs of a crisis and become a mental health first aider alone does not address the prevailing stigma around mental health in the workplace.
"So, in addition, we are developing a culture where support and conversations about mental health are normalised, so that colleagues feel able to reach out for the important support they need."
Zenalpha provides restraint, sedation and analgesia during non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes2.
It is administered intramuscularly and takes effect within 5-15 minutes1, 2.
Dechra says patients also recover more rapidly2, potentially avoiding hospitalisation and allowing them to get home sooner.
Zenalpha contains the active ingredients 0.5 mg/ml medetomidine hydrochloride and 10mg/ml vatinoxan hydrochloride.
Medetomidine is an alpha-2 agonist used for its sedative and analgesic properties.
Vatinoxan is a peripherally selective alpha-2 antagonist which Dechra says has limited penetration across the blood-brain barrier, so it works to antagonise only the alpha-2 receptors located in the periphery, reducing cardiovascular side effects without impacting the quality of sedation or analgesia.
In a study of 223 dogs1 comparing a traditional alpha-2 agonist with Zenalpha, Zenalpha was found to minimise cardiovascular side effects while preserving reliable sedation and analgesia.
Claire Westoby, brand manager at Dechra said: ‘The next generation of alpha-2 agonists have evolved to provide the same effective and reliable sedation and analgesia, but with reduced cardiovascular side effects and a reduced chance of vomiting.
"This improves the sedation experience for the canine patient, as well as reducing the associated stress commonly experienced by veterinary teams and dog owners.”
Matt Gurney FRCVS, an RCVS and EBVS European Specialist in Veterinary Anaesthesia and hospital director at Anderson Moores, said: “It is really exciting to see the launch of an innovative new product, especially one with a unique mechanism of action that will improve the sedation experience for the vet team and our patients.
"Zenalpha not only provides a solution to cases where IV placement is not possible and a rapid onset IM option is required, but it also offers a rapid and complete recovery which ensures that dogs can be reunited with their owners and return home as soon as possible.”
Zenalpha is presented in a 10 ml glass vial in individually packed cardboard boxes.
For more information: www.dechra.co.uk/zenalpha or contact your local Dechra territory manager.
To watch Matt Gurney’s ‘Zennovation in sedation – the next generation of alpha-2 agonists’: www.dechra.co.uk/academy.
The new guidance will remove the absolute requirement for veterinary surgeons to perform a physical examination before prescribing POM medicines, making it instead a matter for your professional judgement.
However, the proposed new guidance also imposes a requirement for veterinary surgeons who do NOT physically examine the animal prior to prescribing to provide a 24/7 follow-up service which includes a physical examination.
Furthermore, the new guidance will state that: "Where the veterinary surgeon is not able to provide this service [the physical exam] themselves, they should arrange for another veterinary service provider to do so. This arrangement should be made before veterinary services are offered and confirmed in writing as part of the conditions of service agreed by the client."
This requirement to provide a physical 24/7 follow-up would appear to safeguard animal welfare and protect against the risk of online-only businesses (in the UK or abroad) with lower overheads cherry-picking the job of prescribing medicines.
It should also protect against veterinary surgeons feeling pressured to prescribe inappropriately, because the new, stricter requirements will make it easier for them to decline to do so.
However, the BVA doesn't agree with the new proposals. It feels that remote prescribing should be delivered under the auspices of a Veterinary Client-Patient-Relationship (VCPR), which, according to the American Veterinary Medical Association, requires a physical examination.
BVA President Malcolm Morley, said: “The changes to ‘under care’ guidance are a watershed moment, so it’s positive to see that they have evolved in response to feedback from the profession. New technology presents exciting opportunities to enhance existing veterinary services and has benefits for practices as well as clients and their animals.
"However, BVA has been very clear that we believe remote prescribing can only be safely delivered where a vet-client-patient relationship has been established.
"This is an internationally recognised concept, and we are disappointed that the RCVS has decided not to embrace it.
“Having voted to implement these changes, it is incumbent upon the RCVS and the profession to scrutinise how they play out.
"At BVA we plan to develop advice and resources to support our members and help them comply with the new guidance and realise any benefits of remote veterinary service provision.’
“It is now vital that a timeframe for a review is quickly put in place, so any negative impacts on animal welfare or the sustainability of veterinary services can be dealt with swiftly.”
Council voted by a majority of 20 to 3 in favour of the changes, which it then decided should come into force between 1st June and 23rd December 2023, subject to a review at the next meeting.
Discuss here.
Boehringer Ingelheim Vetmedica has launched Equisolon 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction (RAO), otherwise known as heaves, in horses.
Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim Vetmedica said: "Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer."
The company says Equisolon should be used in combination with environmental measures to treat RAO.
For further information on Equisolon, contact your Boehringer Ingelheim Vetmedica equine representative or call +44 (0)1344 746959.
To enter the competition, VetSurgeon members just needed to post a 'top tip' that could in any way make life easier, quicker, better or happier for a colleague.
Making use of the new feature on VetSurgeon.org where members can click a link marked 'thank you' to show their appreciation of something useful shared by someone else, VetSurgeon offered five £50 Amazon Vouchers for the most thanked tips shared before the end of November.
The winners are:
Mark Rowland for his tip that Mikki Muzzles make great anaesthesia masks for guinea pigs.
Emma Robinson for her solution to the problem of opening a new bottle "that has one of those annoying little metal caps".
Kate Richardson for her tip, which was to use an elastic band to 'tie' your et tubes in.
Julie Innes for her suggestion to use an elastic/ Velcro back support wrap from the Pound Shop when doing hip scores.
Gillian Mostyn for things you can do with a latex glove.
Virbac Animal Health has announced that its medical castration implant Suprelorin 9.4mg has received a marketing authorisation for use in ferrets.
The neutering of male ferrets (hobs) is recommended to suppress fertility, decrease odour and reduce territorial aggressive behaviour and urinary marking¹. According to Virbac, Suprelorin offers temporary sterilisation but without the need for surgery, and its use prevents the high Luteinizing hormone (LH)/Follicle-stimulating hormone (FSH) levels which occur following surgery and which can play a role in the development of hyperadrenocorticism².
Suprelorin is a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin. Once injected under the skin of healthy, sexually mature and entire ferrets, the continuous low release of deslorelin from the implant causes an interruption of the HPA circuit, leading to a reduction in LH/ FSH levels and therefore testosterone production. This results in a reduction of libido, spermatogenesis and testicle size.
The implant lasts for up to four years, at which stage the ferret can be re-implanted to maintain the effect.
Chris Geddes MRCVS, Virbac Product Manager, said: "For owners looking for a surgery-free route to the castration of male ferrets and the problems it can cause, Suprelorin provides a simple and effective alternative."
Suprelorin 4.7mg has been available for use in dogs since 2008. Suprelorin 9.4mg was launched in 2011.
For further information, please contact your Territory Manager or call Head Office on 01359 243243.
References:
AB Science, a young Paris-based biotech company, has announced the pan-European commercial launch of its veterinary anticancer drug, Masivet
Masivet was approved in November 2008 by the European Medicines Agency (EMEA) for the treatment of dogs with non-resectable grade 2 or 3 mast cell tumours. Masivet's active pharmaceutical ingredient is masitinib, a tyrosine kinase inhibitor. Masitinib, discovered and developed by AB Science, belongs to a therapeutic class of drug known as targeted therapy that is, according to AB Science, revolutionising the treatment of cancer in humans.
Alain Moussy, CEO of AB Science said: "Masivet is the first product ever registered as a cancer treatment in veterinary medicine. AB Science is a dynamic and very entrepreneurial biotech company, and is proud to have introduced a drug that can extend the life of dogs suffering from cancer ahead of the large pharmaceutical companies".
The company says Mastocytoma can be an aggressive cancer with a poor prognosis, and represents up to 20% of all cutaneous canine tumours. Some breeds are particularly susceptible, among them Golden Retrievers, Labradors and Boxers. Cancers have the same prevalence in dogs as in humans (1 dog in 4 will suffer from cancer during its lifetime) but surprisingly, no drugs developed for veterinary medicine with a demonstrated efficacy and safety have ever been approved until the arrival of Masivet.
The company claims two main benefits of the new treatment:
AB Science is a biotech company specialising in developing targeted drugs for high need indications, such as cancers, chronic inflammatory diseases and neurodegenerative disorders. Masitinib is the most advanced drug in the pipeline. Now being marketed in veterinary medicine, masitinib is also under development in humans, with phase 3 clinical studies in pancreatic cancer and in gastrointestinal stromal tumour (GIST).
Alain Moussy said: "This registration in veterinary medicine is good news for the future success of masitinib in humans, for whom we are aggressively developing it in cancers and other indications with high morbidity or pain.
"It is very unusual to develop such an innovative product simultaneously in veterinary and human medicines, and even more so that the product is registered in veterinary medicine first. There is no doubt that experts in human oncology will be watching Masivet's future very closely from now on.. However, people will have to wait a while before benefiting from masitinib because it is unlikely to be available to man before 2012".
For more information, see www.masivet.com and www.ab-science.com